ENTA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

16.14M

-4.83%

-0.807

-23.1%

15.54M

+4.12%

-0.770

-27.36%

15.87M

-13.35%

-0.738

-13.24%

Estimates Revision

The market is revising Upward the revenue expectations for Enanta Pharmaceuticals, Inc. (ENTA) for FY2026, with the revenue forecasts being adjusted by 0.36% over the past three months. During the same period, the stock price has changed by 18.97%.

Revenue Estimates for FY2026

Revise Upward

+0.36%

In Past 3 Month

EPS Estimates for FY2026

Revise Downward

-2.5%

In Past 3 Month

Stock Price

Go Up

+18.97%

In Past 3 Month

6 Analyst Rating

Wall Street analysts forecast ENTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ENTA is 17.00 USD with a low forecast of 9.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

9.00

Averages

17.00

High

24.00

Current: 0.000

Low

9.00

Averages

17.00

High

24.00

JPMorgan

Overweight

initiated

$17

2025-11-14

Reason

JPMorgan

Price Target

$17

2025-11-14

initiated

Overweight

Reason

JPMorgan initiated coverage of Enanta with an Overweight rating and $17 price target. The firm cites the recent Phase 2b data for zelicapavir in respiratory syncytial virus for the positive view. The viral infection has significant unmet need and the study showed faster symptom reduction in the overall population, the analyst tells investors in a research note.

Jefferies

Akash Tewari

Hold

Buy

upgrade

$14 -> $20

2025-10-01

Reason

Jefferies

Akash Tewari

Price Target

$14 -> $20

2025-10-01

upgrade

Hold

Buy

Reason

Jefferies analyst Akash Tewari upgraded Enanta to Buy from Hold with a price target of $20, up from $14.

Jefferies

Hold

Buy

upgrade

$14 -> $20

2025-10-01

Reason

Jefferies

Price Target

$14 -> $20

2025-10-01

upgrade

Hold

Buy

Reason

As previously reported, Jefferies upgraded Enanta to Buy from Hold with a price target of $20, up from $14, based on increased confidence that the company's RSV antiviral zalicapavir could become the first outpatient antiviral approved for RSV. While acknowledging that this week's Phase 2b RSV data in high-risk adults missed its primary endpoint, the firm argues that zalicapavir showed a \"compelling signal\" of about 3-7 days faster symptom resolution in a prespecified subgroup. The firm also thinks Enanta's early-stage oral drugs targeting KIT and STAT6 \"could get more interesting over time,\" the analyst tells investors.

WestPark Capital

NULL -> Buy

initiated

$24

2025-09-02

Reason

WestPark Capital

Price Target

$24

2025-09-02

initiated

NULL -> Buy

Reason

WestPark Capital initiated coverage of Enanta with a Buy rating and $24 price target.

Citizens JMP

Outperform

maintain

$24 -> $25

2025-08-12

Reason

Citizens JMP

Price Target

$24 -> $25

2025-08-12

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on Enanta to $25 from $24 and keeps an Outperform rating on the shares. Enanta Pharmaceuticals expects cash and continuing Mavyret income to fund operations into fiscal 2028, the analyst tells investors in a research note.

H.C. Wainwright

Brandon Folkes

initiated

$20

2025-07-28

Reason

H.C. Wainwright

Brandon Folkes

Price Target

$20

2025-07-28

initiated

Reason

H.C. Wainwright analyst Brandon Folkes assumed coverage of Enanta with a Buy rating and $20 price target. The shares offer a favorable risk/reward at current share levels, driven by the company's upcoming clinical catalysts and diversified pipeline in virology and immunology, the analyst tells investors in a research note. The firm likes the stock into the respiratory syncytial virus Phase 2 data readout.

Valuation Metrics

The current forward P/E ratio for Enanta Pharmaceuticals Inc (ENTA.O) is -4.70, compared to its 5-year average forward P/E of 0.88. For a more detailed relative valuation and DCF analysis to assess Enanta Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

0.88

Current PE

-4.70

Overvalued PE

24.51

Undervalued PE

-22.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.89

Current EV/EBITDA

-5.87

Overvalued EV/EBITDA

10.22

Undervalued EV/EBITDA

-31.99

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

6.73

Current PS

6.43

Overvalued PS

11.23

Undervalued PS

2.22

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 137.44% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

ENTA News & Events

Events Timeline

No data

News

5.0

2025-12-26NASDAQ.COM

Agios Pharmaceuticals (AGIO) Shares Surge 18.6% Following FDA Approval of Aqvesme

4.0

2025-11-15NASDAQ.COM

JP Morgan Begins Coverage of Enanta Pharmaceuticals (ENTA) with Positive Outlook

4.0

2025-11-14Benzinga

Microsoft Analyst Starts Coverage Optimistically; Check Out the Top 3 Initiations for Friday

People Also Watch

Frequently Asked Questions

What is Enanta Pharmaceuticals Inc (ENTA) stock price today?

The current price of ENTA is 13.11 USD — it has decreased -2.46 % in the last trading day.

What is Enanta Pharmaceuticals Inc (ENTA)'s business?

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The Company has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The Company also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.

What is the price predicton of ENTA Stock?

What is Enanta Pharmaceuticals Inc (ENTA)'s revenue for the last quarter?

Enanta Pharmaceuticals Inc revenue for the last quarter amounts to 15.13M USD, increased 3.55 % YoY.

What is Enanta Pharmaceuticals Inc (ENTA)'s earnings per share (EPS) for the last quarter?

Enanta Pharmaceuticals Inc. EPS for the last quarter amounts to -0.87 USD, decreased -36.03 % YoY.

What changes have occurred in the market's expectations for Enanta Pharmaceuticals Inc (ENTA)'s fundamentals?

How many employees does Enanta Pharmaceuticals Inc (ENTA). have?

Enanta Pharmaceuticals Inc (ENTA) has 120 emplpoyees as of January 11 2026.

What is Enanta Pharmaceuticals Inc (ENTA) market cap?

Today ENTA has the market capitalization of 378.39M USD.